Complete metastasectomy in patients with stage IV metastatic melanoma

被引：96
作者：
Ollila, David W. [1 ]
机构：
[1] Univ N Carolina, Sch Med, Div Surg Oncol & Endocrine Surg, Chapel Hill, NC 27599 USA
来源：
LANCET ONCOLOGY | 2006年 / 7卷 / 11期
关键词：
D O I：
10.1016/S1470-2045(06)70938-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with stage IV melanoma have traditionally been managed with various systemic treatments; however, overall survival with this approach has been disappointing. Findings of many retrospective, single-institution, and multicentre studies suggest that participants treated with complete metastasectomy for stage IV metastases have enhanced overall 5-year survival. Complete surgical resection of metastatic disease to stage IV sites-including skin, soft tissue, distant lymph nodes, lungs, or other non-CNS visceral regions-offers the best chance for prolonged survival. This Review will present data lending support to the idea that if complete surgical metastasectomy is technically feasible, then surgery should be the first option for properly selected patients with stage IV melanoma.
引用
收藏
页码：919 / 924
页数：6
相关论文
共 59 条
[1]   Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma [J].
Agarwala, SS ;
Glaspy, J ;
O'Day, SJ ;
Mitchell, M ;
Gutheil, J ;
Whitman, E ;
Gonzalez, R ;
Hersh, E ;
Feun, L ;
Belt, R ;
Meyskens, F ;
Hellstrand, K ;
Wood, D ;
Kirkwood, JM ;
Gehlsen, KR ;
Naredi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :125-133
[2]   Surgery for melanoma metastatic to the gastrointestinal tract [J].
Agrawal S. ;
Yao T.-J. ;
Coit D.G. .
Annals of Surgical Oncology, 1999, 6 (4) :336-344
[3]  
[Anonymous], P AM SOC CLIN ONCOL
[4]   Pulmonary metastases from uterine malignancies: Results of surgical resection in 133 patients [J].
Anraku, M ;
Yokoi, K ;
Nakagawa, K ;
Fujisawa, T ;
Nakajima, J ;
Akiyama, H ;
Nishimura, Y ;
Kobayashi, K .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 127 (04) :1107-1112
[5]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[6]   Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma [J].
Bajetta, E ;
Del Vecchio, M ;
Nova, P ;
Fusi, A ;
Daponte, A ;
Sertoli, MR ;
Queirolo, P ;
Taveggia, P ;
Bernengo, MG ;
Legha, SS ;
Formisano, B ;
Cascinelli, N .
ANNALS OF ONCOLOGY, 2006, 17 (04) :571-577
[7]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .4. PROGNOSTIC FACTORS IN 200 MELANOMA PATIENTS WITH DISTANT METASTASES (STAGE III) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
SMITH, JW ;
MADDOX, WA ;
DURANT, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) :126-134
[8]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[9]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[10]  
BARTH A, 1995, J AM COLL SURGEONS, V181, pA193
123456